- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout | 8 | FierceBiotech | ||
| Fr | XOMA-Aktie steigt nach Übernahme von Turnstone Biologics | 1 | Investing.com Deutsch | ||
| XOMA CORPORATION PREF Aktie jetzt für 0€ handeln | |||||
| Fr | XOMA stock rises after acquisition of Turnstone Biologics | 1 | Investing.com | ||
| Fr | Turnstone Biologics to be acquired by XOMA Royalty | 3 | Seeking Alpha | ||
| Fr | XOMA Royalty to acquire Turnstone Biologics for $0.34 per share | 2 | Investing.com | ||
| Fr | Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right | 97 | GlobeNewswire (Europe) | EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq-CM:... ► Artikel lesen | |
| Fr | XOMA AB: Corrections:Xoma's Biological Purification Technology (FLOW) Shows Strong Results at SCA's Facility | 2 | Cision News | ||
| Fr | XOMA AB: Xoma's Biological Purification Technology (FLOW) Shows Strong Results at SCA's Facility | 1 | Cision News | ||
| 18.06. | XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend | 1 | Seeking Alpha | ||
| 18.06. | XOMA Preferred Shares Series A declares $0.539 dividend | 1 | Seeking Alpha | ||
| 18.06. | XOMA Royalty Corporation: XOMA Royalty Declares Quarterly Preferred Stock Dividends | 1 | GlobeNewswire (USA) | ||
| 16.06. | XOMA AB: Deepened Collaboration between Xoma and Boliden Rönnskär | 10 | Cision News | ||
| 30.05. | XOMA Royalty Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Spotlight Stock Market: Market Notice 95/25 - Last day of trading in Xoma AB's BTA | 1 | Cision News | ||
| 28.05. | XOMA stock holds Buy rating, $104 target from H.C. Wainwright | 6 | Investing.com | ||
| 28.05. | XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 1 | Benzinga.com | ||
| 27.05. | XOMA Royalty purchases mezagitamab royalty rights from BioInvent International for $30M | 1 | Seeking Alpha | ||
| 27.05. | XOMA Royalty Corporation; BioInvent: XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million | 2 | GlobeNewswire (USA) | ||
| 14.05. | XOMA AB: Xoma Reports Strong Water Test Results at Boliden Rönnskär - Negotiations on Next Steps Initiated | 16 | Cision News | ||
| 13.05. | XOMA Royalty GAAP EPS of $0.06, revenue of $15.91M | 1 | Seeking Alpha |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
Das Unternehmen XOMA CORPORATION PREF kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,200 (-0,93 %) liegt der Kurs bei 21,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XOMA CORPORATION PREF finden Sie auf Wallstreet Online.